-
Nat Immunol's Wen Haitao group revealed the mechanism by which the immunosuppressive molecule SUSD2 negatively regulates CD8+ T cell-mediated anti-tumor immune response
Time of Update: 2022-11-01
On October 20, 2022, Professor Wen Haitao's research group (the first author is Dr. Zhao Bao) of The Ohio State University in the United States published a paper entitled SUSD2 suppresses CD8+ T cell antitumor immunity by targeting IL-2 in the journal Nature Immunology Receptor signalin g's article, which reveals the novel immunosuppressive molecule SUSD2 negatively regulates the CD8+ T cell-mediated anti-tumor immune response.
-
Nat Immunol Lai Yuping's team revealed the common mechanism by which the IL-17D/DDX5 axis regulates keratinocyte RNA shear contact with atopic dermatitis and psoriasis
Time of Update: 2022-11-01
To demonstrate the role of DDX5 in skin inflammation, the researchers first analyzed RNA-Seq and single-cell sequencing (scRNA-Seq) results from the skin of healthy controls, AD and psoriasis patients in the GEO database and found DDX5 mRNA expression was significantly reduced in skin lesions in AD and psoriasis patients.
-
Rheumatoid arthritis: Eating the right foods can also relieve joint pain? Research Express
Time of Update: 2022-11-01
Research conclusions and discussions The results of this study showed that during the 16-week trial period, potassium-rich diet and new potassium-rich food supplements (group B) significantly reduced joint pain in patients with RA compared with intake of potassium-rich diet (group A) or daily diet (group C), and pain VAS scores were significantly different between groups (p=0.
-
Nat Immunol Lai Yuping/Dong Chen collaborated to reveal a new regulatory mechanism for the development of inflammatory skin diseases
Time of Update: 2022-11-01
The cytokine interleukin (IL)-17D induces inhibition of DDX5 expression in keratinocytes by activating the CD93-p38 MAPK-AKT-SMAD2/3 signaling pathway and leads to messenger preRNA splicing events, favors the production of membrane-bound intact IL-36 receptors (IL-36R), sacrifices soluble IL-36R (sIL-36R), and selectively amplifies IL-36R-mediated inflammatory responses and skin inflammation 。 In Ddx5∆KC mice with experimental atopic dermatitis or psoriasis, recovery of sIL-36R inhibited skin inflammation and reduced disease phenotypes.
-
NICE Osteoarthritis Guidelines Released! How exactly is it different from the Chinese guide?
Time of Update: 2022-11-01
Assessment ▌NICE guidelines: OA management should be guided by symptoms and physical function, exercise therapy and weight management are the core treatment options, Adjust according to the different needs of patients and participate in decision-making plans.
-
CD(IF=38) 2 articles! Zhang Wenhong of Fudan University and others revealed the cellular basis of homologous or heterologous booster vaccination to enhance the humoral immunity of the new coronavirus
Time of Update: 2022-11-01
Original link: style="margin-right: auto;margin-left: auto;outline: 0px;width: 30px;display: inline-block;">—END—The content is 【iNature】iNatureSARS-CoV-2 vaccine boosters induce a strong humoral immune response, but the cellular mechanism is unknown.
Original link: style="margin-right: auto;margin-left: auto;outline: 0px;width: 30px;display: inline-block;">—END—The content is 【iNature】iNatureSARS-CoV-2 vaccine boosters induce a strong humoral immune response, but the cellular mechanism is unknown.
-
In 4 cases, rheumatic immunology required "guidebook" treatment
Time of Update: 2022-11-01
Recently, the 9th International Forum on Pediatric Rheumatology Immunization was successfully held online, and Professor Li Xiaoxia from Xuanwu Hospital of Capital Medical University raised the following question: In the process of diagnosis and treatment of rheumatology and immunology, doctors choose to use drugs according to international and domestic rheumatology guidelines, or according to doctors' own preferences?
-
First Certificate! The efficacy of leflunomide in the maintenance treatment of lupus nephritis is not inferior to azathioprine research express
Time of Update: 2022-11-01
➤ Maintenance treatment period: Patients enrolled in complete response (CR) or partial response (PR) after 6-9 months of induction period are randomized (1:1) to receive LEF (20mg/d) or AZA (initial dose 50mg/d, target dose 100mg/d) while receiving GCs. The primary endpoint was the time to renal recurrence in patients with 36 months of maintenance therapy, and the key secondary endpoints were the number of patients achieving CR, changes in kidney-related indicators, and safety.
-
Immunity: Pomegranate metabolites can improve the immune system's ability to fight cancer, and clinical trials will be launched soon
Time of Update: 2022-11-01
This study showed that urolithin A (UA), a metabolite of foods such as pomegranates, in the intestinal flora, can promote the expansion of T memory stem cells (Tscm) by activating mitochondrial autophagy, providing the immune system with rejuvenation.
-
NAR: Yin Hang's team at Tsinghua University discovered that USP15 activates the dual mechanism of the cGAS signaling pathway
Time of Update: 2022-11-01
USP15-mediated process of cGAS deubiquitination modification and enhanced phase separation promotes DNA-induced native immune signaling, revealing novel microregulatory mechanisms in native immune pathways.
USP15-mediated process of cGAS deubiquitination modification and enhanced phase separation promotes DNA-induced native immune signaling, revealing novel microregulatory mechanisms in native immune pathways.
-
How can patients with RA experience poor response to multiple drug treatments, how to improve the management of the disease?
Time of Update: 2022-10-26
*For medical professionals onlyMany drugs have failed to effectively control inflammation, how to deal with it?The overall therapeutic goal of rheumatoid arthritis should be to suppress joint lesions
-
Milestone! Remegen Biotech tatacept was approved to conduct a global multi-center phase III clinical trial of SLE in the European Union and China
Time of Update: 2022-10-26
In order to facilitate patients' self-administration, improve the convenience of clinical medication, and the compliance of patients, Remegen has developed the liquid preparation of tetacept - tetacept(study code: RC18-L, prefilled injection), and carried out the global multicenter clinical trial of this liquid dosage form for the treatment of systemic lupus erythematosus.
-
Professor Beicontinental Jian's Review: Excessive negative regulation of type I interferon in patients with Down syndrome undermines their viral immunity Cell Press Youth Promotion Association Review
Time of Update: 2022-10-26
▲ Click the blue word above to follow CellPress cell science ▲ Life SciencesLife scienceAs the world's leading academic publisher in the field of all-science, Cell Press has cooperated with the "Youth
-
Wang Pengfei/Zhang Wenhong et al. evaluated the effectiveness of new crown vaccination and breakthrough infected serum against the latest mutant strain of Omicron
Time of Update: 2022-10-26
As the Omicron variant continues to mutate, many new Omicron sublines have been reported to evade vaccine immunity and viral infection-induced neutralizing antibodies, and the team of Wang Pengfei of Fudan University has previously reported immune escape of Omicron BA.
-
Gout after a light diet? This risk factor is overlooked
Time of Update: 2022-10-26
*For medical professionals onlyStandardized drug treatment is the key to treating goutMany people know that a high-purine diet is easy to cause hyperuricemia and gout, if you choose a light diet, is uric acid reduced to normal, gout can also heal itself?
-
How can I prevent infection in people with systemic lupus erythematosus? Professor Ye Shuang suggested
Time of Update: 2022-10-26
*For medical professionals onlyThe "three-body" problem of lupus and infection, strive to master the balance between immunity, infection and drug treatment~ Recently, the 9th International Forum on Pediatric Rheumatology Immunization and the 15th National Study Class on Pediatric Rheumatic Immune Diseases were held online.
-
When encountering RA patients who do not respond well to biologics, how to effectively control the condition in the next step?
Time of Update: 2022-10-26
*For medical professionals onlyPatients with RA who have high disease activity and do not respond well to multiple drug treatments do you know how to manage such RA?Rheumatoid arthritis (RA) is characterized by polyarticular persistent synovitis, which, if not treated promptly or adequately, can lead to joint structural destruction, loss of function, and eventual disability [1].
-
Hydroxychloroquine relieves renal interstitial fibrosis by inhibiting the PI3K/Akt signaling pathway
Time of Update: 2022-10-25
HCQ reduces apoptosis and inflammatory processes in the UUO kidneys:In summary, the investigators first elucidated hydroxychloroquine to alleviate renal interstitial fibrosis by inhibiting the PI3K/Akt signaling pathway based on network pharmacology, and verified it experimentally.
-
CAR-T is on the rise in the treatment of autoimmune diseases, and a number of product candidates have entered the clinic
Time of Update: 2022-10-25
October 20, 2022 / eMedClub News /--2 October 18, 022, Kyverna Therapeutics Announced that it has submitted an IND application for its autologous CAR-T cell therapy KYV-101 to the FDA for the treatmen
-
Innovative drugs are on the scene, how to optimize the treatment strategy of RA?
Time of Update: 2022-10-25
" Professor Dai Shengming bluntly said, "In the past, there were few treatment drugs for RA, and we could diagnose patients as RA, but there were no good drugs to improve the disease.
